NCT01842126View on ClinicalTrials.gov

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Painful Lumbar RadiculopathyHealthy
Interventions
BIOLOGICAL

BG00010 IV

Ascending Doses intravenous (IV) of BG00010

BIOLOGICAL

BG00010 SC

Ascending Doses subcutaneous (SC) of BG00010

DRUG

Placebo IV

Ascending Doses intravenous (IV) of Placebo

DRUG

Placebo SC

Ascending Doses subcutaneous (SC) of placebo

Trial Locations (1)

Unknown

Center for Human Drug Research, Leiden

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01842126 - Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin) | Biotech Hunter | Biotech Hunter